Day 2 :
Keynote Forum
Gang zhang
Interventional Hospital of Shandong Red Cross Society and Cell Biotechnology Co. Ltd, China
Keynote: Using ‘Mouse Clone Model’ to open the door for human iPSC therapy
Time : 09:00-09:25
Biography:
Gang Zhang has completed his PhD in 2005 from Institute of Zoology, Chinese Academy of Sciences and obtained his Postdoctoral studies from University of Toronto and Harvard Medical School from 2005 to 2015. He discovered the “All or Half” law of recombinant DNA and designed “Mouse Clone Model” to assess the immune-rejection and tumor-formation of iPSCs. Currently, he is the General Director for Research and Development of Interventional Hospital of Shandong Red Cross Society, one of the top hospitals in China. He has published more than 20 papers in reputed journals and is the Editor of 9 famous international journals.
Abstract:
IPSC is one of the most astonishing accomplishments at the 21st century. It not only laid the foundation for the research of reprogramming, but also provided priceless sources for stem cell therapy. However, could iPSCs eventually be adapted into clinical therapy? It is well known that pluripotent stem cells, including ESCs and iPSCs can form tumors and also result in immune rejection. So far, it is uncertain whether tumor-formation and immune-rejection resulted from immune-deficient recipient mice or the donor stem cells. To overcome this confusion, we designed a new mouse model, called “Mouse Clone Model”. This method grants us the ability to generate a grand population of cloned mice and each of them would be originated from the same ICM. When we use them as donors for iPSCs, they would be the same with the original donor ESCs. As a result, we can theoretically perform stem cell transplantation between iPSCs and these mice could mimic the transplantation of iPSCs from the patients into themselves. Our “Mouse Clone Model” has several advantages. Firstly, we can test immunorejection of iPSCs and various tissue specific stem cells. Secondly, we can assess the tumor formation of iPSCs and other stem cell lines. Finally but not lastly, we can investigate the appropriate stages of different stem cells for transplantation. We suggest the stem cell researchers all over the world to investigate the applicability of iPSCs and tissue specific stem cells for therapeutic applications and take advantage of this model.
Keynote Forum
Pedro Morocuo
Centro Empresarial da Marinha Grande, Portugal
Keynote: A novel regenerative medicine approach to reconstruct the temporomandibular joint disk
Time : 9.25 to 10:00
Biography:
Pedro Morouço is the Head of R&D Biofabrication Group at the Centre for Rapid and Sustainable Product Development – Polytechnic Institute of Leiria, Portugal, with a PhD specialized in Biomechanics. His research activity focuses, mostly, on products and processes engineering, aiming to bringing the gap between the lab and in vivo applications. He has Co-edited 3 books, authored and co-authored more than 100 papers published in book-chapters (n=15), international journals (n=40) and international conferences (n=55). He is Editorial Board Member in several international peer-review journals and was distinguished with the New Investigator Award 2014 from ISBS. He coordinates granted national and international research projects and is the Chairman of the CDRsp Advanced Courses on Regenerative Medicine and Workshops on Direct Digital Manufacturing for Medicine.
Abstract:
Temporomandibular joint (TMJ) is a ginglymoarthrodial synovial joint located on both sides of the head, where the mandibular fossa of the temporal bone and the mandibular condyle articulate. A fibrocartilaginous disc between the fossa and the condyle absorbs shock, distributes load, decreases incongruence between joints bony structure and lubricates the surfaces of motion in the TMJ complex mechanical movements. Being the TMJ one of the profusely operational joints in the body (over 2000 periods of motion frequency per day), disorders affecting this joint are quite common. Facial pain induced by temporomandibular disorders has been reported in 9-13% of the general population (with a female: male ratio of 2:1), but only 4-7% look for treatment. These disorders have a considerable impact in the quality of life with chronic and persistent symptoms. The lack of available options illustrates the demanding need to develop optimized and personalized implants to treat TMJ disorders, namely when the TMJ disc needs to be replaced; which can only be achieved with an innovative approach that really mimic the native tissue. This presentation will focus on the developed strategy at CDRsp to overcome the mentioned problems. This work has the support from the Portuguese Government – Foundation for Science and Technology (PTDC/EMS- SIS/7032/2014).